Stockscreener 앱 받기
8.25
2.14%
-0.18
시간 외 거래:
8.27
0.02
+0.24%
전일 마감가:
$8.43
열려 있는:
$8.46
하루 거래량:
121.43K
Relative Volume:
0.56
시가총액:
$71.80M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.4729
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
+14.27%
1개월 성능:
+20.44%
6개월 성능:
+278.44%
1년 성능:
-46.15%
1일 변동 폭
$8.05
$8.46
1주일 범위
$7.09
$8.6279
52주 변동 폭
$1.80
$20.63
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.25 | 62.83M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
What analysts say about CervoMed Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
Is CervoMed Inc. a good long term investmentExponential wealth increase - jammulinksnews.com
What drives CervoMed Inc. stock priceConsistently high returns - jammulinksnews.com
CervoMed Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com
CervoMed’s Dementia Drug Saga Tests Investor Patience And Nerves - Finimize
How CervoMed Inc. stock performs during market volatilityStrategic High Profit Opportunities - Newser
Why CervoMed Inc. stock attracts strong analyst attentionTrend Based Entry Alerts - Newser
What makes CervoMed Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $22.57 - Defense World
CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3 - MSN
CervoMed Inc. to Present Late-Breaking Data on Neflamapimod at Alzheimer’s Association International Congress 2025 - Nasdaq
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 - GlobeNewswire
Late-Breaking Phase 2b Results: CervoMed's Novel DLB Drug Shows Effects on Clinical Progression - Stock Titan
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Dynamic Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 3000E Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Index - MarketScreener
CervoMed Inc. (NASDAQ:CRVO) Shares Bought by Rhumbline Advisers - Defense World
CervoMed Stockholders Approve Key Proposals at Annual Meeting - TipRanks
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Pric - GuruFocus
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Price Held Steady | CRVO Stock News - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appoin - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus
CervoMed appoints Marco Verwijs as EVP, technical operations - TipRanks
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - GlobeNewswire
CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan
CRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - mx.advfn.com
Nuveen Asset Management LLC Acquires 22,104 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Reviewing CervoMed (CRVO) and Its Peers - Defense World
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CervoMed Releases New Business and Financial Information - TipRanks
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Chardan Capital Raises Earnings Estimates for CervoMed - Defense World
Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World
Brokers Set Expectations for CervoMed Q2 Earnings - Defense World
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.51%
자본화:
|
볼륨(24시간):